These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1598 related items for PubMed ID: 19166691

  • 1. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM.
    Am J Cardiol; 2009 Feb 01; 103(3):369-74. PubMed ID: 19166691
    [Abstract] [Full Text] [Related]

  • 2. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan 01; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 3. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E, Ezetimibe Study Group.
    J Womens Health (Larchmt); 2004 Dec 01; 13(10):1101-7. PubMed ID: 15650343
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec 01; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 5. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE, Davidson M, Jones MR, Abby SL.
    Am J Cardiol; 2006 Apr 15; 97(8):1198-205. PubMed ID: 16616026
    [Abstract] [Full Text] [Related]

  • 6. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y.
    Curr Med Res Opin; 2006 May 15; 22(5):823-35. PubMed ID: 16709304
    [Abstract] [Full Text] [Related]

  • 7. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, Ezetimibe Study Group.
    Clin Ther; 2004 Nov 15; 26(11):1758-73. PubMed ID: 15639688
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y.
    Clin Ther; 2006 Jun 15; 28(6):849-59. PubMed ID: 16860168
    [Abstract] [Full Text] [Related]

  • 9. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D.
    Am J Cardiol; 2007 Jun 15; 99(12):1706-1713. PubMed ID: 17560879
    [Abstract] [Full Text] [Related]

  • 10. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS, Bissonnette S, Habib R, Boukas S, Ezetrol Add-On Investigators.
    Ann Pharmacother; 2007 Sep 15; 41(9):1345-51. PubMed ID: 17666579
    [Abstract] [Full Text] [Related]

  • 11. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov 15; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 12. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP.
    Curr Med Res Opin; 2007 Sep 15; 23(9):2183-92. PubMed ID: 17692154
    [Abstract] [Full Text] [Related]

  • 13. The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
    Pitsavos C, Skoumas I, Tousoulis D, Metalinos G, Masoura C, Chrysohoou C, Papadimitriou L, Giotsas N, Toutouza M, Antoniades C, Stefanadis C.
    Int J Cardiol; 2009 May 15; 134(2):280-1. PubMed ID: 18353459
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, Maxwell SE, Tiessen R, Cutler DL.
    Curr Med Res Opin; 2004 Aug 15; 20(8):1185-95. PubMed ID: 15324521
    [Abstract] [Full Text] [Related]

  • 15. Ezetimibe: a novel option for lowering cholesterol.
    Davidson MH.
    Expert Rev Cardiovasc Ther; 2003 May 15; 1(1):11-21. PubMed ID: 15030293
    [Abstract] [Full Text] [Related]

  • 16. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
    Kinlay S.
    J Am Coll Cardiol; 2007 May 22; 49(20):2003-9. PubMed ID: 17512355
    [Abstract] [Full Text] [Related]

  • 17. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
    Gupta M, Szmitko PE, Tsigoulis M, Braga MF, Kajil M, Herjikaka S, Quan A, Teoh H, Verma S.
    J Cardiovasc Pharmacol; 2010 Sep 22; 56(3):241-5. PubMed ID: 20505518
    [Abstract] [Full Text] [Related]

  • 18. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA, Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators.
    Am J Cardiol; 2009 Sep 15; 104(6):798-804. PubMed ID: 19733714
    [Abstract] [Full Text] [Related]

  • 19. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
    Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP, Ezetimibe Study Group.
    Circulation; 2003 May 20; 107(19):2409-15. PubMed ID: 12719279
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
    Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP.
    Am J Cardiol; 2008 Feb 15; 101(4):483-5. PubMed ID: 18312762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.